Glucotrack Initiates Human Trials for Innovative Implantable Glucose Monitor
TL;DR
Glucotrack's CBGM offers real-time accuracy and convenience, setting it apart from rivals in the diabetes management sector.
The CBGM measures glucose levels directly from the blood, providing continuous monitoring for up to three years without external components.
Glucotrack's CBGM aims to positively disrupt diabetes management, offering a less burdensome and more seamless solution for patients.
Glucotrack's clinical study at a renowned cardiology hospital in Brazil is advancing cutting-edge glucose monitoring for patients with type 1 and type 2 diabetes.
Found this article helpful?
Share it with your network and spread the knowledge!
Glucotrack Inc. (NASDAQ: GCTK) has announced the commencement of patient enrollment for human clinical trials of its implantable Continuous Blood Glucose Monitor (CBGM), marking a significant step towards potentially transforming diabetes care. The study, set to take place at the Heart Institute of the Clinical Hospital of the University of São Paulo, aims to validate the device's real-world performance and bring it closer to regulatory approval and commercialization.
The CBGM distinguishes itself from current market offerings through its ability to provide real-time, accurate glucose measurements directly from the blood, rather than interstitial fluid. This approach is considered the gold standard for glucose measurement. Additionally, the implantable format eliminates the need for external wearables and offers an impressive three-year lifespan, addressing key pain points in diabetes management.
Dr. Alexandre Abizaid, a renowned interventional cardiologist, will lead the five-day study involving both type 1 and type 2 diabetes patients. The trial will assess the CBGM's accuracy and performance compared to conventional monitoring methods, with results expected within six to eight weeks.
This development is particularly significant given the size of the global diabetes devices market, which reached $30.31 billion last year according to Grand View Research. Glucotrack's innovation could potentially disrupt this market by offering a solution that combines accuracy, convenience, and long-term use—features that are often mutually exclusive in current devices.
The implications of this technology extend beyond patient comfort. By providing continuous, accurate blood glucose data, the CBGM could enable better disease management, potentially reducing the risk of complications associated with diabetes, including cardiovascular disease. Furthermore, the minimal calibration requirements and long sensor life could significantly reduce the ongoing costs and hassles associated with diabetes care.
As Glucotrack progresses towards regulatory approval, its CBGM technology represents a promising advancement in diabetes care. If successful, it could offer a less burdensome and more effective approach to glucose monitoring, potentially improving the quality of life for millions of people living with diabetes worldwide.
Curated from News Direct
